Bachman brings up the pertinent issue of the cost of therapy for diabetes. As indicated in Table 3 of our article,1 information on the cost of troglitazone was unavailable at the time of our writing. Current pricing data2 indicate that troglitazone is the most expensive of the available oral antidiabetic agents. Although a cost-benefit analysis3 of interventions for diabetes care entails more than a simple algebraic comparison of the retail cost of individual agents, it is nonetheless disturbing that an efficacious agent may be unavailable to otherwise deserving patients who lack adequate health insurance coverage.
Dagogo-Jack S. Cost of Troglitazone Therapy. Arch Intern Med. 1998;158(9):1038. doi:https://doi.org/
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: